Provided by Tiger Trade Technology Pte. Ltd.

Gain Therapeutics, Inc.

1.73
+0.05002.98%
Volume:787.47K
Turnover:1.39M
Market Cap:75.50M
PE:-3.40
High:1.84
Open:1.70
Low:1.69
Close:1.68
52wk High:4.34
52wk Low:1.53
Shares:43.64M
Float Shares:42.34M
Volume Ratio:1.35
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5092
EPS(LYR):-0.6115
ROE:-268.30%
ROA:-95.51%
PB:6.69
PE(LYR):-2.83

Loading ...

Gain Therapeutics Q2 Net Loss Per Share Narrows as R&D Expenses Fall

Reuters
·
Aug 11

Gain Therapeutics reports Q2 EPS (11c), consensus (15c)

TIPRANKS
·
Aug 11

Gain Therapeutics Q2 EPS USD -0.11

THOMSON REUTERS
·
Aug 11

Press Release: Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update

Dow Jones
·
Aug 11

Gain Therapeutics Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Gain Therapeutics Extends Cash Runway Into 2027 Operations

TIPRANKS
·
Jul 17

Gain Therapeutics Names Joanne Taylor Chief Scientific Officer, Promotes Terenzio Ignoni to COO

Reuters
·
Jul 16

Gain Therapeutics - to Commence Phase 2 Study of Rexaceract in Q3 2026

THOMSON REUTERS
·
Jul 16

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

THOMSON REUTERS
·
Jul 16

Gain Therapeutics: Buy Rating Reaffirmed on GT-02287 Clinical Momentum and Differentiated GCase Strategy; $7 Price Target Unchanged

TIPRANKS
·
Jul 03

Analysts’ Opinions Are Mixed on These Healthcare Stocks: LivaNova (LIVN), Gain Therapeutics (GANX) and Tempus AI, Inc. Class A (TEM)

TIPRANKS
·
Jul 02

Gain Therapeutics Buy Rating Reiterated as FDA Clears GT-02287 Phase 2; 12-Month $8 Price Target Maintained

TIPRANKS
·
Jul 01

Gain Therapeutics is Maintained at Buy by BTIG

Dow Jones
·
Jul 01

Stocks to Watch: Aerovironment, Concentrix, Gain Therapeutics, Praxis Precision Medicines

Dow Jones
·
Jun 30

Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial

TIPRANKS
·
Jun 30

Gain Therapeutics receives FDA clearance of GT-02287 IND application

TIPRANKS
·
Jun 30

Gain Therapeutics Wins FDA IND Clearance for Parkinson’s Drug Gt-02287 Phase 2 Trial

Reuters
·
Jun 30

Gain Therapeutics - FDA Decision Allows Initiation of Phase 2 for Gt-2287 in Parkinson's Disease

THOMSON REUTERS
·
Jun 30

Gain Therapeutics - Gt-2287 Phase 2 Clinical Development in U.S. Expected to Initiate During 3Q26

THOMSON REUTERS
·
Jun 30

Gain Therapeutics Shareholders Confirm Board and Auditor Choices

TIPRANKS
·
Jun 26